Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 11387

1.

Systemic methotrexate absorption in a patient receiving intrathecal chemotherapy for acute lymphoblastic leukemia.

Truong H, Sierzchulski AG, Schram S, Litzow M, Hogan WJ.

Leuk Lymphoma. 2019 Dec 13:1-3. doi: 10.1080/10428194.2019.1702184. [Epub ahead of print] No abstract available.

PMID:
31833433
2.

Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting.

Cohen JI, Iwatsuki K, Ko YH, Kimura H, Manoli I, Ohshima K, Pittaluga S, Quintanilla-Martinez L, Jaffe ES.

Leuk Lymphoma. 2019 Dec 13:1-12. doi: 10.1080/10428194.2019.1699080. [Epub ahead of print]

PMID:
31833428
3.

A diffuse large B cell lymphoma with clinical, imaging, and serologic characteristics of neuromyelitis optica spectrum disorder.

Kim YD, Kim TW, Ryu HJ, Lee YH, Jang J, Kim W.

Leuk Lymphoma. 2019 Dec 13:1-3. doi: 10.1080/10428194.2019.1699079. [Epub ahead of print] No abstract available.

PMID:
31833426
4.

Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.

Chandhok NS, Lewis R, Prebet T.

Leuk Lymphoma. 2019 Dec 9:1-16. doi: 10.1080/10428194.2019.1697812. [Epub ahead of print]

PMID:
31814484
5.

Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies.

Schultz MJ, Blackburn PR, Cogbill CH, Pitel BA, Smadbeck JB, Johnson SH, Vasmatzis G, Rech KL, Sukov WR, Greipp PT, Hoppman NL, Baughn LB, Ketterling RP, Peterson JF.

Leuk Lymphoma. 2019 Dec 6:1-4. doi: 10.1080/10428194.2019.1699081. [Epub ahead of print] No abstract available.

PMID:
31809670
6.

Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival.

Arthur C, Jeffrey A, Yip E, Katsioulas V, Nalpantidis A, Kerridge I, Greenwood M, Coyle L, Mackinlay N, Fay K, Enjeti A, Shortt J, Stevenson W.

Leuk Lymphoma. 2019 Dec 6:1-9. doi: 10.1080/10428194.2019.1697876. [Epub ahead of print]

PMID:
31809629
7.

Complete measurable residual disease response after combination chemotherapy with AML-type and ALL-type regimens in pediatric B/myeloid acute bilineal leukemia.

Saito S, Taira C, Matsuda K, Yanagisawa R, Morita D, Shigemura T, Yoshikawa K, Tanaka M, Sakashita K, Mukai S, Shimodaira S, Koike K, Nakazawa Y.

Leuk Lymphoma. 2019 Dec 6:1-4. doi: 10.1080/10428194.2019.1697813. [Epub ahead of print] No abstract available.

PMID:
31809628
8.

The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma.

Zhao Y, Shi Y, Shen H, Zhou, Li L, Zhu J, Yang X, Zheng Y, Zhu L, Ye X, Xie W.

Leuk Lymphoma. 2019 Dec 6:1-8. doi: 10.1080/10428194.2019.1700244. [Epub ahead of print]

PMID:
31809624
9.

WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.

Falconi G, Fabiani E, Ottone T, Piciocchi A, Lavorgna S, Criscuolo M, Fianchi L, Gurnari C, Postorino M, Picardi A, Palmieri R, Lo-Coco F, Voso MT.

Leuk Lymphoma. 2019 Dec 4:1-4. doi: 10.1080/10428194.2019.1699078. [Epub ahead of print] No abstract available.

PMID:
31797711
10.

The option of treatment and outcomes for patients with AIDS-related diffuse large B-cell lymphoma from a resource-limited setting in China.

Zhang Y, Chen S, Lin J, Wang Y, Gui XE, Ke H, Deng D, Routy JP, Cao Q.

Leuk Lymphoma. 2019 Dec 4:1-4. doi: 10.1080/10428194.2019.1697877. [Epub ahead of print] No abstract available.

PMID:
31797709
11.

Platelet-refractoriness and the clinical impact in leukemia population at a metropolitan academic cancer center.

Yang W, Tholpady A, Casteel KN, Rojas-Hernandez C.

Leuk Lymphoma. 2019 Dec 4:1-3. doi: 10.1080/10428194.2019.1697810. [Epub ahead of print] No abstract available.

PMID:
31795873
12.

Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas.

Qian L, Yan M, Zhang W, Zhou D, Zhang Y, Huo L, Luo Y, Zhang Y, Hu S.

Leuk Lymphoma. 2019 Dec 4:1-7. doi: 10.1080/10428194.2019.1697815. [Epub ahead of print]

PMID:
31795794
13.

Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT).

Nahas GR, Komanduri KV, Pereira D, Goodman M, Jimenez AM, Beitinjaneh A, Wang TP, Lekakis LJ.

Leuk Lymphoma. 2019 Dec 3:1-4. doi: 10.1080/10428194.2019.1697814. [Epub ahead of print]

PMID:
31793821
14.

Concerning survival signal for eltrombopag in MDS/AML.

Tao D, Prasad V.

Leuk Lymphoma. 2019 Dec 2:1-2. doi: 10.1080/10428194.2019.1695050. [Epub ahead of print] No abstract available.

PMID:
31786967
15.

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2019 Nov 28:1-12. doi: 10.1080/10428194.2019.1695051. [Epub ahead of print]

PMID:
31779510
16.

Comparison of outcomes of haploidentical donor hematopoietic stem cell transplantation supported by third-party cord blood with HLA-matched unrelated donor transplantation.

Lyu H, Lu W, Yao J, Xiao X, Li Q, Wang J, Mu J, Qi Y, Zhu H, Jiang Y, Li X, Meng J, Yuan T, He X, Jiang E, Han M, Zhao M.

Leuk Lymphoma. 2019 Nov 28:1-8. doi: 10.1080/10428194.2019.1695053. [Epub ahead of print]

PMID:
31777304
17.

Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India.

Vijayasekharan K, Prasad M, Pradhan ND, Phillip D, Gujral S, Shet T, Sridhar E, Kembhavi S, Shah S, Banavali SD, Narula G.

Leuk Lymphoma. 2019 Nov 27:1-7. doi: 10.1080/10428194.2019.1695054. [Epub ahead of print]

PMID:
31774004
18.

Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.

Kawai H, Matsushita H, Akashi H, Furuya D, Kawakami S, Suzuki R, Moriuchi M, Ogawa Y, Kawada H, Nakamura N, Ando K.

Leuk Lymphoma. 2019 Nov 27:1-4. doi: 10.1080/10428194.2019.1691197. [Epub ahead of print] No abstract available.

PMID:
31773997
19.

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.

Sharpley FA, Djebbari F, Fourali S, Kothari J, Lynes JA, McLain-Smith S, Ramasamy K.

Leuk Lymphoma. 2019 Nov 27:1-5. doi: 10.1080/10428194.2019.1683737. [Epub ahead of print] No abstract available.

PMID:
31771382
20.

Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.

Wang M, Fang X, Wang X.

Leuk Lymphoma. 2019 Nov 26:1-13. doi: 10.1080/10428194.2019.1691194. [Epub ahead of print]

PMID:
31766900

Supplemental Content

Loading ...
Support Center